TIDMN4P

RNS Number : 9194F

N4 Pharma PLC

24 March 2022

24 March 2022

N4 Pharma Plc

("N4 Pharma" or the "Company")

Result of Annual General Meeting

N4 Pharma Plc (AIM: N4P), the specialist pharmaceutical company developing Nuvec(R), a novel delivery system for cancer treatments and vaccines, is pleased to announce that at its annual general meeting ("AGM"), held earlier today, all resolutions were duly passed. The results of the proxy voting for the AGM are set out below.

 
  Resolution (*Special    Total Shares          Shares                 % 
       Resolution)            Voted 
                                            For       Against    For     Against 
                         -------------  -----------  --------  -------  -------- 
 
 1. To receive 
  the annual report 
  and audited accounts 
  for the year 
  ended 31 December 
  2021                     20,171,351    20,171,151     200     99.999    0.001 
                         -------------  -----------  --------  -------  -------- 
 2. To re-elect 
  Nigel Theobald 
  as a Director 
  of the Company           20,195,551    20,026,641   168,910   99.164    0.836 
                         -------------  -----------  --------  -------  -------- 
 3. To re-elect 
  David Templeton 
  as a Director 
  of the Company           20,195,551    20,016,641   178,910   99.114    0.886 
                         -------------  -----------  --------  -------  -------- 
 4. To re-appoint 
  Saffery Champness 
  LLP as auditor 
  to the company 
  and authorise 
  the directors 
  to determine 
  their remuneration       20,193,244    19,930,222   263,022   98.697    1.303 
                         -------------  -----------  --------  -------  -------- 
 5. To authorise 
  the Directors 
  to allot shares          20,192,844    19,694,856   497,988   97.534    2.466 
                         -------------  -----------  --------  -------  -------- 
 6*. To disapply 
  pre-emption rights       20,190,444    19,928,374   262,070   98.702    1.298 
                         -------------  -----------  --------  -------  --------

Enquiries:

 
 N4 Pharma Plc                               Via IFC Advisory 
  Nigel Theobald, CEO 
  Luke Cairns, Executive Director 
 
 SP Angel Corporate Finance LLP              Tel: + 44 (0)20 3470 
  Nominated Adviser and Joint Broker          0470 
  Matthew Johnson/Caroline Rowe (Corporate 
  Finance) 
  Vadim Alexandre/Rob Rees (Corporate 
  Broking) 
 
 Turner Pope Investments (TPI) Limited       Tel: +44 (0)20 3657 
  Joint Broker                                0050 
  Andy Thacker 
 IFC Advisory Limited                        Tel: +44 (0)20 3934 
  Financial PR                                6630 
  Graham Herring 
  Zach Cohen

About N4 Pharma

N4 Pharma is a specialist pharmaceutical company developing a novel delivery system for cancer and vaccine treatments using its unique silica nanoparticle delivery system called Nuvec(R).

N4 Pharma's business model is to partner with companies developing novel antigens for cancer and vaccine treatments to use Nuvec(R) as the delivery vehicle to get their antigen into cells to express the protein needed for the required immunity. As these products progress through pre clinical and clinical programs, N4 Pharma will seek to receive up front payments, milestone payments and ultimately royalty payments once products reach the market.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

RAGBBGDXCDDDGDS

(END) Dow Jones Newswires

March 24, 2022 07:32 ET (11:32 GMT)

N4 Pharma (AQSE:N4P.GB)
Graphique Historique de l'Action
De Fév 2025 à Mar 2025 Plus de graphiques de la Bourse N4 Pharma
N4 Pharma (AQSE:N4P.GB)
Graphique Historique de l'Action
De Mar 2024 à Mar 2025 Plus de graphiques de la Bourse N4 Pharma